Chicago, Illinois — August 27, 2025 — Leads & Copy — MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company, announced that a manuscript detailing developments in its Phase 2 THIO-101 clinical trial has been published in the international peer-reviewed open access scientific journal, Cells. The manuscript, titled “Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy,” was authored by oncology researchers from Turkey and the U.S., including MAIA scientists Sergei Gryaznov, Ph.D., and Ilgen Mender, along with MAIA Scientific Advisory Board members Z. Gunnur Dikmen, M.D., Ph.D. and Saadettin Kiliçkap, M.D., M.Sc.
MAIA’s Chairman and CEO Vlad Vitoc, M.D., noted the importance of the findings, highlighting the novel combination strategy of ateganosine sequenced with a checkpoint inhibitor.
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development for non-small cell lung cancer (NSCLC). It induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. It is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
Investor Relations Contact: +1 (872) 270-3518, ir@maiabiotech.com
Source: MAIA Biotechnology, Inc.
